Vikas Sharma, Ph.D.

PERSONAL EXPERIENCE

Dr. Sharma is recognized for his ability to identify and pursue strategic opportunities that create value for both his company and society. His career is marked by a passion for bringing novel treatments to patients and a strong track record of executing complex licensing deals and capital market transactions.

Currently, he serves as Chief Business Officer at QurAlis, a biotechnology company focused on developing precision medicines for neurodegenerative diseases such as ALS and Alzheimer’s. In this role, he is responsible for strategic partnerships, in-licensing and out-licensing of assets, corporate development, operational activities and capital raise.

Before joining QurAlis, Vikas was vice president and head of business development at BioXcel Therapeutics, where he was responsible for all business and corporate development activities. Prior to that, he played an instrumental role in leading licensing deals at MacroGenics with companies such as Incyte Corporation, Roche, and Janssen Pharmaceuticals. Prior to joining MacroGenics, Vikas served as the director, business development at Rexahn Pharmaceuticals where he led the due diligence and execution of licensing deals, M&A, as well as capital markets transactions. Previously, he served as manager, business development, for MedImmune (the global biologics business of AstraZeneca), where he executed multiple licensing transactions. In addition, he served in business development roles with increasing responsibilities at the Children’s Hospital of Philadelphia, Bradley Pharmaceuticals, and Advanced Bioadjuvant. He serves on the board of GO Therapeutics. Vikas earned a PhD and master’s degree in immunology from Rutgers University.